Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Investor Presentation (April 2026)
25 slides from Neurizon Therapeutics's investor presentation, Apr 30, 2026
Slide 1: Neurizon investor briefing presentation
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon investor briefing presentation 30 April 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innova
Slide 2: Neurizon Investor Hub
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view v
Slide 3: Company Presentation April 2026
For personal use only Company Presentation April 2026 ABN 35 094 006 023
Slide 4: Disclaimer
Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation has been Future Matters prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in
Slide 5: Our Vision
For personal use only Our Vision To lead the development of neurodegenerative treatments towards a promising new horizon for patients.
Slide 6: Accelerating Patient Access to Innovative ALS Treatment
Accelerating Patient Driving Access to Innovative ALS Clinical For personal use only Treatment Our Promise Progress Unlocking the potential Delivering commercial of Neurizon to address readiness and high unmet need in stakeholder neurodegenerative value diseases
Slide 7: Corporate Overview
Corporate Overview Mid-stage biotechnology company targeting human neurodegenerative diseases Share Price Performance Capital Structure (AUD$) 29 April 2026 Current Share Price (NUZ/NUZOA) $0.085/ $0.002 For personal use only Closing Price (AUD$) Volume (m) 52 Week Low / High (NUZ) $0.078/ $0.175 0.
Slide 8: Building Momentum Across Key Growth Phases
Building Momentum Across Key Growth Phases For personal use only THEN NEXT NOW Foundation and preparation Data generation and Active clinical execution expansion Executing our clinical programs with We have built the foundation, Delivering data. Creating value. focus, discipline and capital-efficien
Slide 9: NUZ-001: Potential application to range of neurodegenerative diseases
NUZ-001: Potential application to range of neurodegenerative diseases ALS is a current priority, but NUZ-001 has potential application to a range of neurodegenerative diseases. For personal use only NUZ-001 is a mechanism-driven, disease-agnostic approach to treating New preclinical data show NUZ-00
Slide 10: HEALEY Trial: Opportunity for accelerated approval
HEALEY Trial: Opportunity for accelerated approval Initial focus is ALS, a rare disease with high unmet need and the possibility of accelerated approval on Phase 2/3 data. Potential for broader application being developed through pre-clinical program. For personal use only Drug / Approved/ Next Majo
Slide 11: Expanding Relationship with Elanco
Expanding Relationship with Elanco Supply Agreement execution expected in Q2 CY2026 For personal use only License Agreement Strategic Investment Supply Agreement The License Agreement was a foundational step that Elanco is now a top five shareholder in Neurizon and Finalisation of this important agr
Slide 12: 'Regimen-I' HEALEY ALS Platform Trial Expected Key Milestones
‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones For personal use only Q4 2025 Q4 2025 Q1 2026 Q1 2026 Q3-Q4 2026 Q2-Q3 2027 Q3 2027 Q3 2027 5 6 7 8 IND Amendment FDA First Patient First Patient Dosed Enrollment Last Patient Database Topline Data Submission Clearance Screened Complete D
Slide 13: HEALEY ALS Platform Trial Regimen 'I' for NUZ-001
HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001 36-week Double Blind Placebo 36-week Active Treatment Controlled Period Extension Period For personal use only NUZ-001 10 mg/kg Inclusion/Exclusion Criteria 3:1 Randomisation NUZ-001 n=160 participants 10 mg/kg Placebo Primary Endpoint • Change from
Slide 14: Regimen 'I' Participant Enrollment Update
Regimen “I” Participant Enrollment Update For personal use only 57 50 Activated Sites Regimen Assignment 106 36 Master Screening Dosed Participants Numbers referred to above are as of 28 April 2026. Company Presentation April 2026 12
Slide 15: HEALEY: Funding secured
HEALEY: Funding secured Strong shareholder support has secured adequate funding for HEALEY ALS Platform trial1 Neurizon’s funding strategy has been developed with a focus on protecting shareholders’ interests through flexible funding instruments and minimising dilution. This includes the ability to
Slide 16: ALS: High Unmet Need with Significant Value Potential
ALS: High Unmet Need with Significant Value Potential A serious, rapidly progressive disease with limited treatment options. Meaningful innovation in ALS can create value for people living with ALS and the market. For personal use only THE NEED IN ALS WHY NUZ-001 IS RELEVANT COMMERCIAL VALUE POTENTI
Slide 17: ALS: Multiple large-value transactions and deals in recent years
ALS: High Unmet Need with Significant Value Potential Multiple large-value transactions and deals in recent years For personal use only Key ALS Value Reference Point: Shionogi – RADICAVA US$2.5B Transaction Other Recent ALS Deals (April 2026)1 Eli Lilly entered neurodegenerative disease collaboratio
Slide 18: NUZ-001: Strong portfolio protection
NUZ-001: Strong portfolio protection In addition to patent protection, NUZ-001 has US Orphan Drug Designation (ODD) and European Orphan Medicinal Product Designation (OMPD) providing 7 and 10 years of market exclusivity, respectively. For personal use only Patent Families for monepantel 2015 2020 20
Slide 19: Demonstrating Meaningful Progress
Demonstrating Meaningful Progress For personal use only Executed Global Regimen “I” Successful Secured registered Promising Australian License commenced in the manufacture of trademark exploratory top- Patent granted Agreement with HEALEY ALS three registration protection for line results from for N
Slide 20: Disciplined Communication During a High-Execution Period
Disciplined Communication During a High-Execution Period Since April 2025, NUZ maintained regular market disclosure across key operational and value- driving milestones. For personal use only SUBSTANTIVE UPDATES BY CATEGORY A strong cadence of substantive updates reflecting Across 39 unique trading
Slide 21: What Comes Next in Our Growth Strategy
What Comes Next in Our Growth Strategy Our Focus Areas: Potential Value Outcomes: For personal use only Ongoing clinical execution Clinical de-risking driving higher probability of success Continued data generation High-quality data generating long-term value Progressing the Regulatory Pathway Regul
Slide 22: Near-Term Milestones
Near-Term Milestones Objectives • Preclinical updates • HEALEY enrollment updates • Liquid Formulation PK Study Initiation For personal use only • CEO Appointment Preclinical Commercial Supply Ethics Approval for HEALEY enrollment Updates Agreement with Liquid Formulation PK updates • VIC and QLD sh
Slide 23: NUZ-001: Orphan Drug Designated Small Molecule
NUZ-001: Orphan Drug Designated Small Molecule Showing Promising Survival Trends in ALS Well-characterised Drug ✓ Current ALS Treatments ✓ For personal use only • First-in-class oral small molecule • High unmet need for disease modifying • Validated blood brain barrier penetration treatment • Suppor
Slide 24: Q&A
For personal use only Q&A
Slide 25: Thank You
For personal use only THANK YOU Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com
Neurizon Therapeutics — Investor Presentation (April 2026) on 6ix